Drug Profile
Research programme: Alzheimer's disease antibody therapeutics - Alector/Johnson & Johnson Innovative Medicine
Alternative Names: Alzheimer's disease antibody therapeutics - Alector/Johnson & Johnson Innovative MedicineLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Alector
- Developer Alector; Johnson & Johnson Innovative Medicine
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Jul 2018 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)
- 10 Mar 2014 Early research in Alzheimer's disease in USA (unspecified route)